| Not Yet Recruiting | Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma NCT07379489 | Tongji Hospital | — |
| Not Yet Recruiting | TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma NCT07340502 | Tongji Hospital | — |
| Not Yet Recruiting | Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3 NCT07353333 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | REGULUS: MRI-guided Adaptive SABR for Liver Cancers NCT07223307 | Stanford University | Phase 2 |
| Not Yet Recruiting | TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hyperte NCT07350070 | Tongji Hospital | Phase 2 |
| Not Yet Recruiting | Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC NCT07350824 | Tongji Hospital | N/A |
| Not Yet Recruiting | Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular NCT07352007 | Lei ZHAO | Phase 2 |
| Not Yet Recruiting | Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment NCT07168668 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | Y-90 Treatment Response Using Transarterial Radioembolization NCT07145801 | Thomas Jefferson University | Phase 2 |
| Not Yet Recruiting | A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Pati NCT07119931 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carci NCT07300488 | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of NCT07334483 | GrandPharma (China) Co., Ltd. | Phase 2 |
| Recruiting | Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line NCT07099274 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | HOPE Against Cancer Recurrence in HCC NCT06717919 | Philipp Dutkowski | Phase 4 |
| Recruiting | SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis NCT06823375 | Chinese University of Hong Kong | Phase 2 |
| Not Yet Recruiting | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC NCT06984718 | Akeso | Phase 2 |
| Recruiting | Effect of the HCC Liver-Link Intervention NCT06728293 | Indiana University | N/A |
| Not Yet Recruiting | Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer NCT07007286 | Peking University First Hospital | — |
| Recruiting | A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stag NCT06844357 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Phase I Study of OriC902 in Treatment of Advanced HCC NCT06891742 | Peking University | Phase 1 |
| Active Not Recruiting | A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatoc NCT07009470 | Tongji Hospital | N/A |
| Recruiting | IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carc NCT06757881 | Shanghai Zhongshan Hospital | Phase 1 |
| Recruiting | A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurren NCT06930573 | The First Affiliated Hospital of Zhengzhou University | Phase 4 |
| Not Yet Recruiting | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC NCT06584071 | Biotheus Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors NCT06764836 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Recruiting | SBRT in HCC With Oligoprogression on First-line Immunotherapy NCT06434480 | Chinese University of Hong Kong | N/A |
| Recruiting | Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440 | Chen Xiaoping | Phase 2 |
| Recruiting | Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models NCT06463444 | Chen Xiaoping | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learn NCT06311916 | Chen Xiaoping | Phase 4 |
| Recruiting | Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. NCT06311942 | Chen Xiaoping | Phase 4 |
| Recruiting | Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma NCT06311929 | Chen Xiaoping | Phase 4 |
| Unknown | Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients NCT06285149 | Henan Cancer Hospital | Phase 2 |
| Unknown | Population-wide Research for HBV-related Liver Diseases in Maoming City NCT06184347 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma NCT07272200 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | N/A |
| Not Yet Recruiting | Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy NCT05965388 | Wen-hong Zhang | — |
| Recruiting | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules NCT06184152 | University of Texas Southwestern Medical Center | N/A |
| Recruiting | Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Rese NCT06904014 | Lei ZHAO | Phase 2 |
| Not Yet Recruiting | SALT for Liver Cirrhosis With HCC NCT06069947 | RenJi Hospital | N/A |
| Recruiting | CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Re NCT06560827 | CARsgen Therapeutics Co., Ltd. | Phase 1 |
| Unknown | Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atez NCT06024252 | Zhongda Hospital | — |
| Not Yet Recruiting | Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC NCT05840133 | Qianfoshan Hospital | — |
| Recruiting | Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure NCT06413017 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | CXD101 in Immunotherapy-related Liver Cancer NCT05873244 | Stephen Chan Lam | Phase 2 |
| Withdrawn | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC NCT05212922 | Eucure (Beijing) Biopharma Co., Ltd | Phase 2 |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Unknown | Study of Serum Tumor Markers of HBV Associated HCC NCT05825196 | Qianfoshan Hospital | — |
| Recruiting | DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial NCT05788835 | Xuhua Duan | N/A |
| Recruiting | Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) NCT05781568 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | — |
| Recruiting | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma NCT06527495 | Assiut University | Phase 1 / Phase 2 |
| Recruiting | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related NCT06617000 | SCG Cell Therapy Pte. Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Unknown | Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC NCT05592171 | University of Pisa | N/A |
| Unknown | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC NCT05544253 | West China Hospital | Phase 2 / Phase 3 |
| Unknown | Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma NCT05458115 | Anhui Provincial Hospital | — |
| Recruiting | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma NCT05341557 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Unknown | Association Between Serum Ferritin Level and Severity of Liver Disease and Development of HCC in Cirrhotic Pat NCT05401890 | Assiut University | — |
| Recruiting | Multi-analyte Blood Test Clinical Trial NCT05199259 | Helio Genomics | — |
| Completed | ICIs With and Without MWA in Advanced Hepatocellular Carcinoma NCT06581497 | The First People's Hospital of Neijiang | — |
| Unknown | Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study NCT05202015 | Charite University, Berlin, Germany | — |
| Recruiting | HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients NCT04455932 | Concord Repatriation General Hospital | N/A |
| Unknown | Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Por NCT05022628 | Anhui Provincial Hospital | Phase 4 |
| Unknown | cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC NCT05025592 | Peking University Cancer Hospital & Institute | — |
| Unknown | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma NCT05178043 | Suzhou Kintor Pharmaceutical Inc, | Phase 2 |
| Unknown | Artificial Intelligence and Hepatocellular Carcinoma NCT05637788 | Humanitas Clinical and Research Center | — |
| Completed | The Utility of Breath Biopsy as a Screening Tool for HCC NCT04326491 | University of Aberdeen | — |
| Recruiting | Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT NCT04843176 | The University of Hong Kong | N/A |
| Recruiting | Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC NCT04522544 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Unknown | Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study NCT04640363 | Chinese PLA General Hospital | — |
| Recruiting | TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma NCT04988945 | The University of Hong Kong | Phase 2 |
| Unknown | Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Rese NCT04682210 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | Cabozantinib in Hepatocellular Carcinoma NCT04588051 | Stephen Chan Lam | Phase 2 |
| Completed | The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma NCT04542837 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma NCT04472767 | University of California, Irvine | Phase 2 |
| Recruiting | Optimizing Y90 Therapy for Radiation Lobectomy NCT04390724 | Northwestern University | — |
| Completed | Neoadjuvant Anti-PD1 in HCC NCT05471674 | Dr Tan-to CHEUNG | Phase 2 |
| Unknown | Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC NCT04611373 | The First Affiliated Hospital of Zhengzhou University | Phase 3 |
| Active Not Recruiting | GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC NCT04251117 | Geneos Therapeutics | Phase 1 / Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant NCT03960008 | Lahey Clinic | Phase 3 |
| Active Not Recruiting | Composite Warming Strategy Reduces Intraoperative Hypothermia in Open Hepatectomy for Liver Cancer NCT06766773 | The First People's Hospital of Neijiang | N/A |
| Unknown | Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation NCT04232722 | Zhejiang University | Phase 2 |
| Unknown | Dual Arterial Phase Liver CT in Patients With Suspected Portal Hypertension NCT04195971 | Seoul National University Hospital | N/A |
| Unknown | Renal Protocol Protection in CKD Patients NCT04024514 | Seoul National University Hospital | N/A |
| Completed | Low-dose Y90 Treatment Planning for HCC NCT04172714 | Emory University | N/A |
| Unknown | PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT NCT04165174 | Huazhong University of Science and Technology | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Sol NCT04172506 | Akeso | Phase 1 / Phase 2 |
| Completed | Intraprocedural Assessment of Ablation Margins Using Computed Tomography Co-registration in Primary Liver Tumo NCT04123340 | Leiden University Medical Center | Phase 2 |
| Unknown | Multi-center Clinical Application of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma NCT03985644 | Zhejiang University | — |
| Unknown | Netrin-1 & Hepatocellular Carcinoma HCC NCT04766736 | Hospices Civils de Lyon | — |
| Completed | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) NCT03893695 | Suzhou Kintor Pharmaceutical Inc, | Phase 1 / Phase 2 |
| Unknown | Novel Treatment of Advanced Hepatocellular Carcinoma NCT03950518 | The First Affiliated Hospital of Zhengzhou University | Phase 3 |
| Completed | Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy NCT03817736 | The University of Hong Kong | Phase 2 |
| Completed | VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy NCT06253364 | Chen Xiaoping | — |
| Active Not Recruiting | Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in NCT06461936 | Chen Xiaoping | — |
| Unknown | Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. NCT02715492 | Sherief Abd-Elsalam | Phase 3 |
| Unknown | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC NCT03601598 | Harbin Medical University | Phase 1 / Phase 2 |
| Completed | Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study NCT03437382 | Leiden University Medical Center | N/A |
| Active Not Recruiting | Pembrolizumab in Hepatocellular Carcinoma NCT03419481 | CCTU | Phase 2 |
| Unknown | Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microsp NCT05227482 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 2 |
| Unknown | Risk of HCC in Cirrhotic Patients Post DAAs Ttt NCT03414554 | Assiut University | — |
| Recruiting | Evaluation of Risk of hEpatocellular Carcinoma NCT06523179 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | N/A |
| Completed | Multidisciplinary Management of HCC in Elderly Patients NCT03875417 | Azienda Policlinico Umberto I | — |
| Unknown | The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma NCT03314532 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Suspended | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation NCT02935478 | St. Louis University | N/A |
| Terminated | A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver NCT02966223 | Indiana University | N/A |
| Unknown | Phase IB/II Study of NRT Combined With Radiotherapy for Advanced HCC NCT03199807 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1 / Phase 2 |
| Unknown | Treatment of Intermediate-stage Hepatocellular Carcinoma NCT03274427 | The First Affiliated Hospital of Zhengzhou University | Phase 3 |
| Unknown | Treatment of Advanced Hepatocellular Carcinoma NCT03278444 | The First Affiliated Hospital of Zhengzhou University | Phase 3 |
| Active Not Recruiting | RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resect NCT04032860 | West China Hospital | Phase 4 |
| Completed | "Double Low-Dose" DECT for HCC Imaging NCT03045445 | Seoul National University Hospital | N/A |
| Unknown | Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular C NCT03097848 | Southwest Hospital, China | N/A |
| Unknown | ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy NCT03104920 | feng xiaobin | N/A |
| Unknown | Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC NCT02187081 | Southwest Hospital, China | N/A |
| Completed | Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. NCT02971696 | Ain Shams University | Phase 3 |
| Completed | Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening NCT02833298 | Icahn School of Medicine at Mount Sinai | N/A |
| Terminated | Statin With Palliative Therapy for HCC NCT02785874 | Taipei Medical University WanFang Hospital | N/A |
| Terminated | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma NCT02575339 | Kathy Miller | Phase 1 / Phase 2 |
| Completed | LifePearl-Doxo Pharmacokinetic (PK) Study NCT02548780 | Terumo Europe N.V. | N/A |
| Completed | Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma NCT02645981 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 / Phase 3 |
| Completed | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors NCT02705105 | Kyowa Kirin, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Mali NCT02659852 | Yonsei University | N/A |
| Completed | 18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib NCT02977754 | Istituto Clinico Humanitas | — |
| Unknown | p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma NCT02561546 | Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 |
| Completed | Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization NCT02471313 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Modeling Cancer-specific Prognosis in Liver Transplantation for Hepatocellular Carcinoma (HCC) NCT02898415 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI NCT02415283 | Beijing 302 Hospital | — |
| Completed | ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibr NCT04173520 | Egyptian Liver Hospital | — |
| Completed | Non Transplantable Recurrence After Percutaneous Thermal Ablation of HCC NCT05202184 | University Hospital, Montpellier | — |
| Unknown | Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L NCT02232490 | Immunitor LLC | Phase 3 |
| Completed | Small and Steatotic Hepatocellular Carcinoma NCT03428321 | University Hospital, Montpellier | — |
| Unknown | Combined Treatment of RFA and Sorafenib on Recurrent HCC NCT01470495 | Southwest Hospital, China | N/A |
| Completed | A Study of HCC High Risk Group Using Two Surveillance Tools NCT02675920 | Seoul National University Hospital | — |
| Completed | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors NCT03176485 | University of Arizona | N/A |
| Unknown | Open Label Trial of Immunotherapy for Advanced Liver Cancer NCT02256514 | Immunitor LLC | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver T NCT02182687 | Lahey Clinic | Phase 2 |
| Completed | Radiofrequency Ablation Using Cooled-Wet Electrode NCT02675894 | Seoul National University Hospital | N/A |
| Completed | Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma NCT02229071 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Completed | Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®) NCT02675881 | Seoul National University Hospital | N/A |
| Completed | Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI) NCT01871545 | Icahn School of Medicine at Mount Sinai | N/A |
| Completed | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Can NCT01356628 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | ISP-TACE Versus TACE for HCC With PVTT NCT03108248 | Zhongda Hospital | — |
| Unknown | Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) NCT01265576 | Vicus Therapeutics | Phase 2 |
| Completed | Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT NCT02985034 | Seoul National University Hospital | — |
| Completed | Equity and Efficacy of Allocation Priority for Liver Transplantation Patients With MELD≥30 in Italy NCT04530240 | University of Bologna | — |
| Completed | A Novel MSE Score to Predict rHCC Patients NCT05450874 | Tongji Hospital | — |
| Completed | A New Conception About Individualized Treatment Allocation for HCC NCT06008548 | Tang-Du Hospital | — |
| Completed | Added Value of Gadoxetic Acid-enhanced Liver MRI NCT03045419 | Seoul National University Hospital | — |
| Completed | Hepatectomy for Early-stage HCC Patients With CSPH NCT05402644 | Tongji Hospital | — |
| Completed | A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib NCT01387555 | Jennerex Biotherapeutics | Phase 2 |
| Completed | Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Crite NCT04069416 | Ain Shams University | — |